Impact Biomedical Inc.
IBO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001834105
In the last 90 days, Impact Biomedical Inc. insiders filed 0 open-market purchases and 1 sale; 23 institutions reported holding it in 13F filings for Q2 2026, worth $1.76M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Impact Biomedical Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +3 vs. Q1 2025
- Shares held
- 508.0K
- +122.2K (+31.7%) vs. Q1 2025
- Total value
- $328.2K
- −$7.16K (−2.1%) vs. Q1 2025
- New holders
- 5
- 4 more added
- Sold out
- 2
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IBO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $1.76M |
| Q1 2026 | 21 | $2.23M |
| Q4 2025 | 24 | $726.3K |
| Q3 2025 | 21 | $357.8K |
| Q2 2025 | 20 | $328.2K |
| Q1 2025 | 17 | $335.4K |
| Q4 2024 | 11 | $76.1K |
| Q3 2024 | 10 | $59.3K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Impact Biomedical Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CWM, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 3 | $2 | 0.00% | 00.0% | Unchanged |
| Signature Resources Capital Management, LLC | 4 | $3 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 29 | $19 | 0.00% | −1,000−97.2% | Reduced |
| FMR LLC | 36 | $23 | 0.00% | +36 | New |
| Bank of America Corp | 80 | $52 | 0.00% | +63+370.6% | Added |
| Newbridge Financial Services Group, Inc. | 86 | $56 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,449 | $938 | 0.00% | −2,317−61.5% | Reduced |
| Citigroup Inc | 8,784 | $5.68K | 0.00% | +8,784 | New |
| HRT Financial LP | 10,326 | $6.00K | 0.00% | −57,832−84.8% | Reduced |
| StoneX Group Inc. | 10,794 | $6.99K | 0.00% | +10,794 | New |
| State Street Corp | 11,797 | $7.63K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 22,700 | $14.7K | 0.00% | +22,700 | New |
| Susquehanna International Group, LLP | 30,824 | $19.9K | 0.00% | +30,824 | New |
| Vanguard Group Inc | 32,437 | $21.0K | 0.00% | −94,009−74.3% | Reduced |
| Ferguson Wellman Capital Management, Inc | 36,364 | $23.6K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 39,725 | $25.7K | 0.00% | +23,558+145.7% | Added |
| Geode Capital Management, LLC | 49,869 | $32.3K | 0.00% | +26,669+115.0% | Added |
| BlackRock, Inc. | 252,730 | $163.6K | 0.00% | +222,055+723.9% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −60,315−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −7,800−100.0% | Sold out |